Cardiologia

#ACC22 – Estudo randomizado | Diltiazem não melhorou significativamente a disfunção vasomotora coronariana em casos de angina e artérias coronárias não obstrutivas.

5 Abr, 2022 | 12:06h

Efficacy of Diltiazem to improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries (ANOCA): Results of the EDIT-CMD randomized clinical trial – JACC: Cardiovascular Imaging (link para o resumo – $ para o texto completo)

Comentários:

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD – TCTMD

EDIT-CMD: Diltiazem Not Effective in Reducing Coronary Vasomotor Dysfunction, Improving Angina or QOL in ANOCA Patients – American College of Cardiology

 

Comentário no Twitter

#ACC22 #JACCIMG SimPub: In this first performed RCT in pts w/ ANOCA, authors show that 6 weeks therapy w/ #diltiazem didn't substantially improve CVDys, symptoms or #QoL when compared w/ placebo, but did ⬇️ prevalence of epicardial spasm. https://t.co/An8v4JHkl4 #CardioTwitter pic.twitter.com/D0fRG0PewG

— JACC Journals (@JACCJournals) April 2, 2022

 

---

Estudo de coorte baseado em registro | Regurgitação mitral recorrente após MitraClip: fatores preditivos, morfologia e implicação clínica.

5 Abr, 2022 | 11:55h

Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication – Circulation: Cardiovascular Interventions

 

Comentário no Twitter

Residual MR is a predictive factor for recurrent MR in both primary and secondary MR treated with #MitraClip. What predictive factors are different for the two? #AHAJournals #Cardiotwitter #ACCFIT #structuralheart #mitravalvehttps://t.co/gTkiOytNeu pic.twitter.com/HafPkyxNQ6

— CircInterventions (@CircIntv) March 25, 2022

 

---

Revisão do estado de arte | A equipe neurocardíaca e o tratamento centrado no paciente de AVC isquêmico.

1 Abr, 2022 | 13:13h

The Heart Brain Team and Patient-Centered Management of Ischemic Stroke – JACC: Advances

---

Diretriz de consenso | Fisiologia coronariana invasiva em pacientes com angina e doença arterial coronariana não obstrutiva.

1 Abr, 2022 | 13:04h

Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership – Heart

---

Testes genéticos identificaram uma variante causadora de doença em 10% dos sobreviventes de parada cardíaca inexplicada.

1 Abr, 2022 | 13:00h

Importance of genetic testing in cardiac arrest – European Heart Journal

 

Comentário no Twitter

🫀Importance of genetic testing in unexplained cardiac arrest (UCA)

♦️Genetic testing identifies a disease-causing variant in 🔟% of UCA

♦️Majority of variants located in genes associated with cardiomyopathy in absence of a diagnosis#CardioTwitter

🔗https://t.co/tLcqeDPx1S pic.twitter.com/rTbN1W86oa

— 𝗔𝗯𝗱𝗲𝗹𝘀𝗮𝗹𝗮𝗺 𝗕𝗲𝗻 𝗦𝗮𝗮𝘂𝗱 (@BenSaaud) March 30, 2022

 

---

Metanálise de 56 estudos randomizados controlados | Intervenções farmacológicas para doença de Kawasaki em crianças.

1 Abr, 2022 | 12:59h

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials – eBioMedicine

Comentário: Network meta-analysis rates treatments for Kawasaki disease – medwire News

---

Metanálise de estudos randomizados | Clopidogrel é melhor que aspirina na prevenção secundária de eventos cardiovasculares.

1 Abr, 2022 | 12:25h

P2Y₁₂ Inhibitor versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Trials – European Heart Journal Open

Comentário: Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention – TCTMD

 

Comentário no Twitter

Happy to share our paper in @ESC_Journals. In this meta-analysis of randomized trials, we found that as compared with aspirin, P2Y12i was associated with 11% and 19% reduction in MACE and MI respectively. https://t.co/Y3Gstzgfu6

— Devika Aggarwal (@devikagg) March 30, 2022

 

---

Revisão | Insuficiência cardíaca avançada: tratamento médico, diuréticos, inotrópicos e cuidados paliativos.

1 Abr, 2022 | 12:12h

Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care – ESC Heart Failure

---

Posicionamento científico AHA/ASA | Tratamento endovascular e trombólise para AVC isquêmico agudo em pacientes com incapacidade premórbida ou demência.

31 Mar, 2022 | 13:32h

Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association – Stroke

Comunicado de imprensa: Stroke treatments safe and effective for people with existing disability or dementia – American Heart Association

 

Comentário no Twitter (fio – clique para saber mais)

1/ Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients with Pre-morbid Disability or Dementia

Authors: @draravindganesh @pecouille @SMGreenbergNeur @Doctorjfred @mayank_G0 @NAsdaghi @GPerue

Published today in @StrokeAHA_ASA: https://t.co/9VdIvGDNoN pic.twitter.com/CgET4ygCHu

— AHA Science (@AHAScience) March 28, 2022

 

---

Revisão | Morte súbita cardíaca na doença cardíaca congênita.

31 Mar, 2022 | 13:20h

Sudden cardiac death in congenital heart disease – European Heart Journal

 

Comentário no Twitter

Sudden cardiac death in congenital heart disease – state-of-the-art review https://t.co/Oz5Lbp8XKZ @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/Bu6m4tK8rL

— European Society of Cardiology Journals (@ESC_Journals) March 28, 2022

 

---